Drug Type Bispecific antibody |
Synonyms anti-CLDN6-CD137 BsAb |
Target |
Mechanism 4-1BB agonists(Tumor necrosis factor receptor superfamily member 9 agonists), CLDN6 modulators(Claudin 6 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 1 | CN | 23 Feb 2024 | |
CLDN6-positive Solid Tumors | IND Approval | CN | 24 Oct 2023 | |
Stomach Cancer | IND Approval | CN | 24 Oct 2023 | |
Endometrial Carcinoma | IND Approval | US | 18 Aug 2023 | |
Non-Small Cell Lung Cancer | IND Approval | US | 18 Aug 2023 | |
Ovarian Cancer | IND Approval | US | 18 Aug 2023 | |
Testicular Neoplasms | IND Approval | US | 18 Aug 2023 |